Xavier Salvatella, ICREA researcher at IRB Barcelona, proposes a new approach to combat prostate tumour cells that have become unresponsive to the treatments currently available.
The incidence of prostate cancer is increasing worldwide. In the US and Europe, it is one of the most common tumours and among the main causes of death by cancer.
The technology supplement Innovadores of the newspaper El Mundo has echoed on the award of 220,000 euros to three biomedical innovation projects underway at IRB Barcelona. This funding has been given by the Agency for Management and University and Research Grants (AGAUR, acronym in Catalan) of the Catalan Government, with the support of ERDFs.
The labs headed by Angel R. Nebreda, Ernest Giralt and Roger Gomis secure funding for further development of three medical applications.
The three projects will receive 220,000 euros from the "Knowledge Industry" programme, which is run by the Catalan Government and cofunded by ERDFs.
On May 27-28, the Barcelona Science Festival will bring a hundred science activities to the Parc de la Ciutadella.
IRB Barcelona is to participate in the Festival by giving a talk on Network Medicine and holding two workshops for a wide range of public.
p38α is a protein involved in chronic inflammatory diseases and cancer, among other pathological conditions.
Published in the journal eLife, the study provides a deeper understanding of the structure of this protein, thereby paving the way for the development of more effective inhibitors.
These findings are the result of combining fundamental biological data using computational techniques.
The journal ecancer.org echoes on the study performed by basic and clinical researchers at IDIBELL, VHIO, IDIBAPS and IRB Barcelona. Researchers have been able to recreate and characterise the process through which resistance to chemotherapy is acquired in orthotopic animal models of breast cancer.
Published by Stem Cell Reports, the study unveils the possibility of reversing this resistance after a period of rest from the treatment.
Link to ecancer.org
Other media mentions
The journal Phys.org reports on the research performed by IRB Barcelona scientists. In the study, these researchers have provided an integrative picture of the p38α activation mechanism and new insights into the molecular effects of various molecules that regulate the enzymatic activity of this protein.
The first author of this study is Antonija Kuzmanic, an EU Marie Curie COFUND fellow who is undertaking postdoctoral training simultaneously in two IRB Barcelona labs — the Molecular Modelling and Bioinformatics Laboratory and the Signalling and Cell Cycle Laboratory.
Link to Phys.org...
Angel R. Nebreda, ICREA Research professor and group leader of the Signalling and Cell Cycle Laboratory at IRB Barcelona, was invited by Radio Benavente (Cadena SER) to talk about his career as a Molecular Biologist, his research in cell biology and his ERC Proof of Concept grant to investigate new breast cancer therapies.
During the interview, Angel R. Nebreda gives an advice to young students who want to become scientists: “Scientific research demands a lot of curiosity, you have to be interested in the unknown, ask when you don't understand something, and be strongly motivated”.
In response to a question about the role of science in Spanish society, he says: “We have to...
On 6 September, IRB Barcelona joined 252 institutions throughout Europe to sign the “Statement supporting European Directive 2010/63/EU”, promoted by the European Animal Research Association to endorse European legislation that protects animals used for scientific purposes. In Spain, the initiative was defended by COSCE, the Confederation of Spanish Science Societies.
Research Associate Ivan del Barco says that the Directive “forces you to really think about your experiment and minimise the use of animals to get your results.”
The Government of Catalonia has published a news article that summarises the competitiveness of Catalan research centres and universities in the European Research Council (ERC) Call in 2015. The scientist Angel R. Nebreda, who belongs to the Oncology Programme and already holds an ERC Advanced Grant, has now been awarded an ERC Proof of Concept to develop drugs against breast cancer.